CLINICAL TRIALS PROFILE FOR DANOCRINE

All Clinical Trials for Danocrine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Beijing Hospital	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Beijing Municipal Science & Technology Commission	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Beijing Tongren Hospital	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Navy General Hospital, Beijing	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Qilu Hospital of Shandong University	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01667263 ↗	The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia	Completed	Peking University People's Hospital	Phase 2	2012-06-01	Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
NCT01732445 ↗	Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis	Completed	National Cancer Institute (NCI)	Phase 2	2013-04-01	This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.

Clinical Trial Conditions for Danocrine

Condition Name

Condition Name for Danocrine
Intervention	Trials
Immune Thrombocytopenia	3
Primary Myelofibrosis	2
Secondary Myelofibrosis	1
Thrombocytopenia	1

Condition MeSH

Condition MeSH for Danocrine
Intervention	Trials
Thrombocytopenia	4
Purpura, Thrombocytopenic, Idiopathic	4
Primary Myelofibrosis	2
Polycythemia	1

Clinical Trial Locations for Danocrine

Trials by Country

Trials by Country for Danocrine
Location	Trials
United States	14
France	11
Poland	9
Hungary	8
Italy	8

Trials by US State

Trials by US State for Danocrine
Location	Trials
New York	2
Arizona	2
Texas	1
Pennsylvania	1
Ohio	1

Clinical Trial Progress for Danocrine

Clinical Trial Phase

Clinical Trial Phase for Danocrine
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Danocrine
Clinical Trial Phase	Trials
Recruiting	2
Completed	2
Active, not recruiting	1

Clinical Trial Sponsors for Danocrine

Sponsor Name

Sponsor Name for Danocrine
Sponsor	Trials
Peking University People's Hospital	4
Qilu Hospital of Shandong University	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for Danocrine
Sponsor	Trials
Other	10
Industry	1
NIH	1